Dr. Goldstein is a human geneticist whose scientific career has focused on genetic diversity, the genetics of disease and pharmacogenetics, leading to the co-founding of Actio Biosciences. He was previously director of the Institute for Genomic Medicine, and a professor of genetics and development at Columbia University, with the mission to integrate genetics and genomics into research, patient care and education. Previously, Dr. Goldstein directed Duke University’s Center for Human Genome Variation. He has discovered over 30 disease-causing genes and syndromes, in particular for neurological and infectious diseases. He has also served as an advisor to numerous pharmaceutical companies, including as AstraZeneca’s chief genomics adviser, where he led an initiative focused on the discovery of new targets and biomarkers linked to molecular mechanisms of disease across multiple therapeutic areas. Dr. Goldstein is a scientific co-founder of Praxis Precision Medicines, a publicly traded clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by neuronal imbalance.